Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
...
Next
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Comment by
BlaineBorg
on Jun 21, 2021 12:01pm
RE:RE:Question for the CEO, Mr. Moreau @ Algernon Pharmaceuticals
To sum up the CEO's answer to the SH question about market valuation...What the CEO basically said is it's his belief the market should be valuing a DMT story about a Phase 1 clinical trial
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Comment by
BlaineBorg
on Jun 21, 2021 11:49am
RE:Question for the CEO, Mr. Moreau @ Algernon Pharmaceuticals
Please allow me rephase the question: For the past 16 months, the COVID-19 news releases make up 75% of all the news releases targeting a specific disease. That's a ratio of 3 out of
...more
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m
posted Nov 13, 2024 9:00am by
Freegold Ventures Limited
-
|
Four specific holes were drilled to facilitate additional metallurgical testing and were strategically designed to collect representative material from the deposit while improving infill drilling efforts. Approximately ~2,400 meters of ½ PQ core (~ 20 tonnes) have been shipped to BaseMet Labs in Kamloops, BC, where a comprehensive suite of metallurgical testing is currently underway ...read more
(22)
•••
B52paul
X
View Profile
View Bullboard History
Post by
B52paul
on Jun 21, 2021 11:35am
Countdown !
www.datecountdown.com/?&d=07%2f05%2f2021+12%3a00+AM&t=FDA+#timer1
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Post by
BlaineBorg
on Jun 21, 2021 11:29am
Question for the CEO, Mr. Moreau @ Algernon Pharmaceuticals
As of March 2020 to the present, here is the percentage of news releases individually targeting COVID-19, IPF & Chronic Cough, DMT, and Cancer. COVID-19 - 63% IPF & Chronic Cough - 6% DMT -
...more
(22)
•••
B52paul
X
View Profile
View Bullboard History
Post by
B52paul
on Jun 21, 2021 10:57am
70 days almost !
https://howlongagogo.com/date/2021/april/26
(22)
•••
B52paul
X
View Profile
View Bullboard History
Post by
B52paul
on Jun 21, 2021 10:55am
70 days. Almost !
VANCOUVER, British Columbia, April 26, 2021 (GLOBE NEWSWIRE) The FDA guidelines show that the Company can expect a response within 70 days, although with the topic of the meeting being a COVID-19
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Comment by
BlaineBorg
on Jun 19, 2021 3:07pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:The IPF and Chronic Cough study is now on the back burner.
You're missing a big piece of the equation which is the safety issues of new drugs. Ifenprodil is not a new drug. "NP-120 (Ifenprodil – brand name Cerocal) was initially developed by
...more
(5)
•••
TheBearInTheWoods
X
View Profile
View Bullboard History
Comment by
TheBearInTheWoods
on Jun 19, 2021 11:35am
RE:RE:RE:RE:RE:RE:RE:RE:The IPF and Chronic Cough study is now on the back burner.
I agree with your post about Mackie, but for one thing. The CEO is a snake oil salesman, no one wants in for phase II as the odds of success are 30.1%. It's a lottery ticket that takes time with a
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Comment by
BlaineBorg
on Jun 19, 2021 11:09am
RE:RE:RE:RE:RE:RE:RE:The IPF and Chronic Cough study is now on the back burner.
What we saw was Mackie smacking the c-rap out of Algernon Pharmaceuticals with their analysis of the COVID-19 Phase II Topline data readout. If the CEO crawls back to them with another PP that would
...more
(5)
•••
TheBearInTheWoods
X
View Profile
View Bullboard History
Comment by
TheBearInTheWoods
on Jun 19, 2021 1:23am
RE:RE:RE:RE:RE:RE:The IPF and Chronic Cough study is now on the back burner.
Management raised plenty of money for their wages and business expenses, retail just didn't see Mackie doing what they did. Great job on management for taking a .03 stock to .58 and doing a raise
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Comment by
BlaineBorg
on Jun 18, 2021 8:52pm
RE:RE:RE:RE:RE:The IPF and Chronic Cough study is now on the back burner.
It can't get any worse because they don't know when they will achieve full enrollment. The timeline is already costing us big-time while another bs pp is on the horizon. If he cant land some
...more
(79)
•••
Danorrn
X
View Profile
View Bullboard History
Comment by
Danorrn
on Jun 18, 2021 8:37pm
RE:RE:RE:RE:The IPF and Chronic Cough study is now on the back burner.
I just got spammed by stockhouse and the CEO trying to pump the company out of the basement. He actually made it sound worse.
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Post by
BlaineBorg
on Jun 18, 2021 5:14pm
The CEO is the only full-time employee but where's...
Business Advisory Board - Algernon Pharmaceuticals Ambassador (Rtd) Howard Gutman Ambassador (Rtd) Gutman acted, during his distinguished career over the past three decades, as a
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Post by
BlaineBorg
on Jun 18, 2021 12:10pm
$3 Billion COVID-19 Therapy Handout! Can we get any of it?
Biden Administration to Invest $3 Billion from American Rescue Plan as Part of COVID-19 Antiviral Development Strategy Whole-of-Government Effort Will Develop Next Generation of
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Comment by
BlaineBorg
on Jun 18, 2021 2:36am
RE:RE:RE:RE:RE:The IPF and Chronic Cough study is now on the back burner.
There was a fire in 1 hospital halfway around the world the following month that affected 75% of the data. Hence, further delays and a readout that finally came on the very last day of Q1 2021. Kinda
...more
Prev
...
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Star Diamond Corporation Announces Third Quarter 2024 Results
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits
Explained: The Psychology of Options Trading with Practical Tips
Meet the Top 5 Best Online Brokerages in Canada
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
Gold, growth and sustainability in focus for this resource company